{
"id":"mk19_b_hm_s8",
"subspecialtyId":"hm",
"title":"Transfusion Medicine",
"jsonContent":{
"type":"section",
"id":"mk19_b_hm_s8",
"title":{
"__html":"Transfusion Medicine"
},
"titleNode":{
"type":"section-title",
"hlId":"e1fce3",
"children":[
"Transfusion Medicine"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_hm_s8_1",
"title":{
"__html":"Blood Donor Screening"
},
"titleNode":{
"type":"section-title",
"hlId":"f05872",
"children":[
"Blood Donor Screening"
]
},
"children":[
{
"type":"p",
"hlId":"39604c",
"children":[
"Blood donor screening comprises questions regarding the donor's general health and any high-risk behaviors. Blood undergoes laboratory testing for hepatitis B and C viruses, HIV, human T-cell lymphotropic virus I/II, and West Nile virus; serologic testing for syphilis; and, in select regions of the country, testing for antibodies to ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Trypanosoma cruzi"
]
},
" (agent for Chagas disease), ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Babesia"
]
},
", and Zika virus. Platelet components are also screened for bacterial contamination before being released for transfusion."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"e15de5",
"children":[
"Donated whole blood is screened for hepatitis B and C viruses, HIV, human T-cell lymphotropic virus I/II, and West Nile virus; undergoes serologic testing for syphilis; and, in select regions of the country, is tested for antibodies to ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Trypanosoma cruzi"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Babesia"
]
},
", and Zika virus."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_2",
"title":{
"__html":"Blood Group Antigens, Pretransfusion Compatibility Testing, and the Direct Antiglobulin Test"
},
"titleNode":{
"type":"section-title",
"hlId":"0afc76",
"children":[
"Blood Group Antigens, Pretransfusion Compatibility Testing, and the Direct Antiglobulin Test"
]
},
"children":[
{
"type":"p",
"hlId":"9968be",
"children":[
"A type and screen comprises ABO/Rh blood group determination and a screening test for unexpected (non-ABO) antibodies. For procedures in which blood transfusion is not invariably needed, a type and screen showing no unexpected antibodies eliminates the need for specific crossmatching (compatibility testing); blood can be quickly crossmatched when and if the decision to transfuse is made. If unexpected antibodies are found, a specific crossmatch is performed to ensure that erythrocytes in the selected unit do not express the antigen(s). Blood is always matched for Rh status in women of childbearing potential and in patients with anti-RH antibodies but may not be matched for other patients requiring massive transfusion. Women of childbearing age or younger who are Rh negative and patients previously sensitized to Rh antigens should never receive Rh-positive blood."
]
},
{
"type":"p",
"hlId":"20e9c1",
"children":[
"A direct antiglobulin (Coombs) test is performed to look for IgG or complement coating a patient's erythrocytes and is part of the investigation for suspected hemolytic transfusion reactions (acute or delayed), autoimmune hemolytic anemia, and hemolytic disease of the newborn."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"4c50ab",
"children":[
"Women of childbearing age or younger who are Rh negative and patients previously sensitized to Rh antigens should never receive Rh-positive blood."
]
},
{
"type":"keypoint",
"hlId":"5c4f88",
"children":[
"For procedures in which blood transfusion is not invariably needed, a type and screen showing no unexpected antibodies eliminates the need for routine preprocedure crossmatching of individual units."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_2_1",
"title":{
"__html":"Blood Components"
},
"titleNode":{
"type":"section-title",
"hlId":"75f210",
"children":[
"Blood Components"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_hm_s8_2_1_1",
"title":{
"__html":"Packed Red Blood Cells"
},
"titleNode":{
"type":"section-title",
"hlId":"253b58",
"children":[
"Packed Red Blood Cells"
]
},
"children":[
{
"type":"p",
"hlId":"7c440e",
"children":[
"Packed red blood cells (PRBCs) are erythrocytes suspended in anticoagulant-preservative solution at a hematocrit level of 55% to 65%. Transfusion of one unit of PRBCs to an average-sized, nonbleeding adult raises the hematocrit level by 3% and the hemoglobin level by 1 g/dL (10 g/L) (for transfusion product modifications, see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t25",
"wrapId":"1",
"children":[
"Table 25"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_hm_t25"
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_2_1_2",
"title":{
"__html":"Plasma"
},
"titleNode":{
"type":"section-title",
"hlId":"b20a42",
"children":[
"Plasma"
]
},
"children":[
{
"type":"p",
"hlId":"178bdb",
"children":[
"Plasma contains coagulation factors and all other plasma proteins. Plasma transfusion is indicated to restore coagulation factors for which specific factor concentrates are not available or in the setting of multiple acquired deficiencies, as in warfarin overdose when 4-factor prothrombin complex concentrates (PCCs) are unavailable."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_2_1_3",
"title":{
"__html":"Cryoprecipitate"
},
"titleNode":{
"type":"section-title",
"hlId":"e262a3",
"children":[
"Cryoprecipitate"
]
},
"children":[
{
"type":"p",
"hlId":"f307cf",
"children":[
"Cryoprecipitate is the fraction of plasma that precipitates when fresh frozen plasma is thawed at 1.0 to 4.0 °C (33.8-39.2 °F). It contains fibrinogen, von Willebrand factor, and factor VIII and is used to treat hypofibrinogenemia and disseminated intravascular coagulation (DIC). Cryoprecipitate is also used empirically in uremic bleeding. Eight to 10 units of cryoprecipitate (from 8-10 donors) are pooled before transfusion."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_2_1_4",
"title":{
"__html":"Platelets"
},
"titleNode":{
"type":"section-title",
"hlId":"256c18",
"children":[
"Platelets"
]
},
"children":[
{
"type":"p",
"hlId":"52b546",
"children":[
"Platelet concentrates are derived from whole blood. Donations by apheresis yield platelet products equivalent to approximately five platelet concentrates (platelets derived from whole blood donation) and raise the platelet count by around 20,000 to 30,000/μL (20-30 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L). Platelet transfusions are needed for patients with thrombocytopenia undergoing general surgery (platelet count <50,000/μL [50 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L]) or neurosurgery (platelet count <100,000/μL [100 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L]) or those who are actively bleeding. Platelets are also transfused to prevent spontaneous bleeding in most stable, afebrile patients whose platelet count is less than 10,000/μL (10 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L) or in select circumstances, such as in patients with acute promyelocytic leukemia with a platelet count less than 30,000 to 50,000/μL (30-50 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L). Platelets should generally not be used to treat patients with an established diagnosis of thrombotic thrombocytopenic purpura and should be limited to managing life-threatening bleeding in patients with immune thrombocytopenia (see ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t25",
"wrapId":"2",
"children":[
"Table 25"
]
}
]
},
" for platelet modifications)."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_hm_t25"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"ee44ef",
"children":[
"Transfusion of one unit of packed red blood cells to an average-sized, nonbleeding adult raises the hematocrit by 3% and the hemoglobin level by 1 g/dL (10 g/L); transfusion to patients with anemia increases oxygen-carrying capacity."
]
},
{
"type":"keypoint",
"hlId":"cf6bab",
"children":[
"Cryoprecipitate contains a concentrated amount of fibrinogen and is used to treat hypofibrinogenemia occurring in disseminated intravascular coagulation."
]
},
{
"type":"keypoint",
"hlId":"07e515",
"children":[
"Platelets are not generally indicated in otherwise stable patients with chronic thrombocytopenia until the platelet count decreases to less than 10,000 (10 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_2_2",
"title":{
"__html":"Plasma Derivatives and Recombinant Coagulation Factors"
},
"titleNode":{
"type":"section-title",
"hlId":"5542ea",
"children":[
"Plasma Derivatives and Recombinant Coagulation Factors"
]
},
"children":[
{
"type":"p",
"hlId":"6a17cd",
"children":[
"Plasma pooled together from thousands of donors is fractionated into derivatives such as albumin, Rh immune globulins, or coagulation factor concentrates ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t26",
"wrapId":"3",
"children":[
"Table 26"
]
}
]
},
")"
]
},
". Plasma derivatives are processed to reduce the risk of infectious disease transmission. Recombinant factor concentrates (not containing any donor plasma) have become the standard of care for younger patients with hemophilia A and B (factor VIII and IX deficiency, respectively). Recombinant porcine factor VIII has been shown to provide effective hemostasis in patients with acquired hemophilia A."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_hm_t26"
]
},
{
"type":"p",
"hlId":"214d0e",
"children":[
"Four-factor PCCs contain factors II, VII, IX and X and are the preferred product for patients experiencing life-threatening bleeding while taking warfarin. Although 3-factor PCCs are available, the 4-factor product is preferred. Inappropriate use of PCCs carries a thrombotic risk, so they should not be used in patients without life-threatening bleeding, before elective invasive procedures, or in patients with chronic liver disease. PCCs contain residual heparin and are contraindicated in patients with heparin-induced thrombocytopenia."
]
},
{
"type":"p",
"hlId":"fe50b2",
"children":[
"Activated factor VII, which also has considerable prothrombotic risk, is used to manage hemophilia in patients with high inhibitor titers and acquired hemophilia in some patients."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"2a9ef2",
"children":[
"Recombinant factor concentrates (not containing any donor plasma) are the standard of care for younger patients with hemophilia A and B."
]
},
{
"type":"keypoint",
"hlId":"883262",
"children":[
"Four-factor prothrombin complex concentrates are the preferred product for patients experiencing life-threatening bleeding while taking warfarin."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_3",
"title":{
"__html":"Blood Management"
},
"titleNode":{
"type":"section-title",
"hlId":"3fb192",
"children":[
"Blood Management"
]
},
"children":[
{
"type":"p",
"hlId":"a80a71",
"children":[
"Patient blood management is a multidisciplinary strategy that achieves a clinically relevant goal rather than corrects an abnormal laboratory finding, identifies and corrects specific causes of anemia that eliminate the need for transfusion, and reduces iatrogenic blood loss."
]
},
{
"type":"p",
"hlId":"8f689f",
"children":[
"A restrictive transfusion threshold of a hemoglobin level less than 7 g/dL (70 g/L) has been shown to be as safe and effective as more liberal thresholds, except in patients with acute coronary syndrome or acute stroke. This restrictive threshold does not apply to patients who are hemodynamically unstable or actively bleeding and should not be applied to symptomatic patients with rapidly decreasing hemoglobin concentrations."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"444b93",
"children":[
"A restrictive transfusion threshold (hemoglobin level <7 g/dL [70 g/L]) provides equivalent outcomes as a more liberal threshold in most patients; those with acute coronary syndrome, acute stroke, acute symptomatic anemia, or acute blood loss might require transfusion at a higher hemoglobin level."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_4",
"title":{
"__html":"Transfusion Complications"
},
"titleNode":{
"type":"section-title",
"hlId":"11e094",
"children":[
"Transfusion Complications"
]
},
"children":[
{
"type":"p",
"hlId":"29034f",
"children":[
"Transfusion reactions occur in approximately 1% of transfusions. Although fatal reactions are rare (incidence of 1:200,000-400,000 units), the leading causes are hemolysis, transfusion-related acute lung injury, and transfusion-associated circulatory overload."
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_4_1",
"title":{
"__html":"Hemolytic Reactions"
},
"titleNode":{
"type":"section-title",
"hlId":"9fc290",
"children":[
"Hemolytic Reactions"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_hm_s8_4_1_1",
"title":{
"__html":"Acute Hemolytic Transfusion Reactions"
},
"titleNode":{
"type":"section-title",
"hlId":"4a6e53",
"children":[
"Acute Hemolytic Transfusion Reactions"
]
},
"children":[
{
"type":"p",
"hlId":"42c0b5",
"children":[
"Acute ABO-incompatible hemolytic transfusion reactions usually result from clerical errors at the time of specimen collection or blood administration. Electronic barcode systems reduce such errors. Patient and specimen identification can be particularly problematic in high turnover areas. Acute hemolytic reactions manifest with fever and flank pain. This can lead to hypotension, diffuse bleeding, DIC, hemoglobinuria, and death. Rarely, high titer A (or B) antibodies found in platelet units initiate hemolysis. Management requires abrupt transfusion termination, because the degree of hemolysis is proportional to the volume transfused. Volume expansion and supportive care for associated complications (DIC, acute kidney injury) are required. An investigation into the cause of the reaction is initiated in each case."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_4_1_2",
"title":{
"__html":"Delayed Hemolytic Transfusion Reaction"
},
"titleNode":{
"type":"section-title",
"hlId":"6fc738",
"children":[
"Delayed Hemolytic Transfusion Reaction"
]
},
"children":[
{
"type":"p",
"hlId":"de4537",
"children":[
"Antibodies to non-ABO blood group antigens occur after exposure through transfusion or pregnancy but may not be detectable when transfusion is needed years later. Re-exposure leads to an anamnestic response and delayed hemolysis of the transfused antigen-positive erythrocytes, typically 7 to 14 days after transfusion. The causative association between a decreasing hematocrit and a previous transfusion is not always appreciated. Laboratory investigation will reveal a positive direct antiglobulin test, and the blood bank will be able to identify the target antigen. Patients should be informed regarding their alloimmunization status so they can communicate this information to other health care providers for subsequent surgery or other care. Some jurisdictions outside the United States have transfusion “antibody registries” for this purpose."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"7d88fc",
"children":[
"Acute hemolytic transfusion reactions manifest with fever and flank pain, which can progress to hypotension, diffuse bleeding, and hemoglobinuria; discontinuing the transfusion is the most important step in treatment."
]
},
{
"type":"keypoint",
"hlId":"eb2560",
"children":[
"A delayed hemolytic transfusion reaction occurs 1 to 2 weeks after transfusion and should be evaluated with a direct antiglobulin test (the result will be positive)."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_4_2",
"title":{
"__html":"Nonhemolytic Transfusion Reactions"
},
"titleNode":{
"type":"section-title",
"hlId":"1689ac",
"children":[
"Nonhemolytic Transfusion Reactions"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_hm_s8_4_2_1",
"title":{
"__html":"Transfusion-Associated Circulatory Overload"
},
"titleNode":{
"type":"section-title",
"hlId":"b33782",
"children":[
"Transfusion-Associated Circulatory Overload"
]
},
"children":[
{
"type":"p",
"hlId":"3db1fe",
"children":[
"Transfusion-associated circulatory overload is an underrecognized problem but may be the most common serious complication of blood transfusion, affecting 1% to 8% of transfusion recipients. Risk factors include older age, pre-existing cardiovascular or kidney disease, and rapid administration rate. Signs and symptoms include respiratory distress within 6 hours of transfusion, positive fluid balance, elevated central venous pressure, elevated B-type natriuretic peptide, and compatible radiographic findings of pulmonary edema. Therapy consists of diuretics and a slower rate of blood administration."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_4_2_2",
"title":{
"__html":"Transfusion-Related Acute Lung Injury"
},
"titleNode":{
"type":"section-title",
"hlId":"5a9eeb",
"children":[
"Transfusion-Related Acute Lung Injury"
]
},
"children":[
{
"type":"p",
"hlId":"fc71b2",
"children":[
"Transfusion-related acute lung injury (TRALI) is defined as noncardiogenic pulmonary edema that occurs within 6 hours of transfusion. Patients present with dyspnea, fever, and hypotension without signs of volume overload. Radiographic findings usually resemble acute respiratory distress syndrome. Most cases of TRALI occur because of HLA or neutrophil-specific antibodies in donors that bind to and activate recipient leukocytes in the pulmonary vasculature. Screening donors for these antibodies reduces the incidence. Management is supportive and includes supplemental oxygen or mechanical ventilation. The prognosis is better, and the recovery is quicker than in patients with typical acute respiratory distress syndrome. TRALI is unlikely to recur in subsequent transfusions."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_4_2_3",
"title":{
"__html":"Febrile Nonhemolytic Transfusion Reaction"
},
"titleNode":{
"type":"section-title",
"hlId":"edb794",
"children":[
"Febrile Nonhemolytic Transfusion Reaction"
]
},
"children":[
{
"type":"p",
"hlId":"ee3ceb",
"children":[
"Febrile nonhemolytic transfusion reaction is common, occurring in about 1% of transfusion episodes, and is mediated by proinflammatory cytokines elaborated by donor leukocytes during storage. Symptoms encompass a temperature increase of 1.0 °C (1.8 °F) to greater than 38.0 °C (100.4 °F) within 4 hours of transfusion or chills and rigors even in the absence of a fever. The differential diagnosis of fever occurring in association with transfusion includes hemolysis and septic transfusion reaction. The direct antiglobulin test result is negative. Antipyretics are used for treatment, but routine prophylaxis with antipyretics is not warranted. Leukoreduction reduces the incidence."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"cf434a",
"children":[
"Signs and symptoms of transfusion-associated circulatory overload include respiratory distress within 6 hours of transfusion, positive fluid balance, elevated central venous pressure, elevated B-type natriuretic peptide, and compatible radiographic findings of pulmonary edema."
]
},
{
"type":"keypoint",
"hlId":"5edf50",
"children":[
"Transfusion-related acute lung injury is defined as noncardiogenic pulmonary edema that occurs within 6 hours of transfusion and is managed similarly to other causes of acute respiratory distress syndrome."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_4_3",
"title":{
"__html":"Infectious Complications"
},
"titleNode":{
"type":"section-title",
"hlId":"00400a",
"children":[
"Infectious Complications"
]
},
"children":[
{
"type":"p",
"hlId":"45e17f",
"children":[
"Risk of infection ranges from 1:300,000 for hepatitis B and West Nile viruses to 1:1 million for infections such as hepatitis C virus and HIV. In addition to these infections, bacterial contamination may occur, especially in platelet components that are stored at room temperature. Bacterial testing is performed before issuing the unit, but the risk is still reported to be 1:1000 to 1:3000 units. Erythrocyte components may rarely be infected with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Yersinia"
]
},
", which thrive in a cold, iron-rich environment."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_4_4",
"title":{
"__html":"Allergic Reactions and Anaphylaxis"
},
"titleNode":{
"type":"section-title",
"hlId":"fe3109",
"children":[
"Allergic Reactions and Anaphylaxis"
]
},
"children":[
{
"type":"p",
"hlId":"5be0e0",
"children":[
"Pruritus and urticaria occur in 1% to 5% of recipients during or after transfusion. Because the reaction may be donor specific, prophylaxis with antihistamines or glucocorticoids for future transfusions is unwarranted."
]
},
{
"type":"p",
"hlId":"256317",
"children":[
"Anaphylactic or anaphylactoid reactions are rare. Manifestations include angioedema, stridor, abdominal symptoms, and hypotension. Patients may require epinephrine, bronchodilators, or fluid resuscitation. Protein deficiency (IgA or haptoglobin) should be ruled out. Documentation of severe IgA deficiency with anti-IgA antibodies necessitates using washed cellular blood components or plasma components from IgA-deficient donors for future transfusions."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"f1d5a9",
"children":[
"No evidence supports the routine use of antihistamine or glucocorticoid prophylaxis in patients with a history of mild allergic transfusion reactions."
]
},
{
"type":"keypoint",
"hlId":"15c23d",
"children":[
"Manifestations of anaphylactic or anaphylactoid transfusion reactions include angioedema, stridor, abdominal symptoms, and hypotension and should prompt an investigation for an underlying protein deficiency (IgA or haptoglobin)."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_4_5",
"title":{
"__html":"Transfusion-Associated Graft-versus-Host Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"5a971e",
"children":[
"Transfusion-Associated Graft-versus-Host Disease"
]
},
"children":[
{
"type":"p",
"hlId":"4bf636",
"children":[
"Transfusion-associated graft-versus-host disease is a rare but fatal complication in which donor lymphocytes in a cellular blood product (erythrocytes or platelets) engraft in an immunocompromised recipient and cause toxic effects in the bone marrow, skin, liver, and gastrointestinal tract. Patients at risk include those receiving chemotherapy for autoimmune disorders or malignancy, patients with aplastic anemia or other forms of immunodeficiency, patients who have undergone stem cell or other transplantation, recipients of blood components from first-degree relatives, and premature infants. Prevention involves irradiation of cellular blood components. Patients who have undergone stem cell transplantation typically require irradiated blood components indefinitely."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"445ca7",
"children":[
"Patients who have undergone stem cell transplantation typically require irradiated blood products to prevent transfusion-associated graft-versus-host disease."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_5",
"title":{
"__html":"Transfusion in Special Circumstances"
},
"titleNode":{
"type":"section-title",
"hlId":"5d613a",
"children":[
"Transfusion in Special Circumstances"
]
},
"children":[
{
"type":"p",
"hlId":"bb4c3e",
"children":[
"Massive transfusion is defined as the transfusion of one blood volume in 24 hours or 50% in 4 hours. When whole blood is lost and replaced with crystalloid and PRBCs, a dilutional coagulopathy develops that is often exacerbated by hypothermia, acidosis, and liver injury as well as concomitant DIC. Contemporary practice is to transfuse plasma and platelets concurrently with PRBCs to avoid the development of dilutional coagulopathy. During resuscitation, patients must be monitored for electrolyte disturbances such as hypocalcemia, hyperkalemia or hypokalemia, and metabolic alkalosis."
]
},
{
"type":"p",
"hlId":"c9e12f",
"children":[
"Warm reactive IgG erythrocyte autoantibodies are panagglutinins that interfere with antibody identification and crossmatch procedures. Transfusions should be avoided in patients with warm antibody autoimmune hemolytic anemia, but if transfusion is urgently needed, ABO/Rh-matched but crossmatch-incompatible blood may be issued. Patients who have never been pregnant or received a transfusion are unlikely to have hidden alloantibodies that could cause more fulminant acute hemolytic transfusion reactions. The hospitalist, hematologist, and blood bank specialist should closely coordinate the care of these patients."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"ef8574",
"children":[
"As patients requiring massive transfusion are resuscitated, they must be monitored for electrolyte disturbances such as hypocalcemia, hyperkalemia or hypokalemia, and metabolic alkalosis."
]
},
{
"type":"keypoint",
"hlId":"999409",
"children":[
"Patients with warm autoimmune hemolytic anemia have autoantibodies that may make crossmatch-compatible units impossible to find; these patients should be transfused with ABO and Rh type-specific, crossmatch-incompatible blood."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_6",
"title":{
"__html":"Therapeutic Apheresis"
},
"titleNode":{
"type":"section-title",
"hlId":"3b2b60",
"children":[
"Therapeutic Apheresis"
]
},
"children":[
{
"type":"p",
"hlId":"51d2b2",
"children":[
"Apheresis procedures collect whole blood and separate it into components. Specific components (plasma, platelets, erythrocytes, leukocytes) can be removed as needed. Fluid is replaced with colloid and crystalloid. Complications include hypocalcemia, thrombocytopenia, and hypofibrinogenemia, so laboratory studies must be monitored. Therapy for thrombotic thrombocytopenic purpura is more appropriately characterized as plasma exchange because fresh frozen plasma is provided as the replacement fluid. The same cell separators can be used to perform plateletpheresis, erythrocyte exchange transfusion, and other procedures in patients with specific indications ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t27",
"wrapId":"4",
"children":[
"Table 27"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_hm_t27"
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s8_7",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood. 2019;133:1854-64. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30808637",
"target":"_blank"
},
"children":[
"PMID: 30808637"
]
},
" doi:10.1182/blood-2018-11-833996"
]
},
{
"type":"reference",
"children":[
"Carson JL, Triulzi DJ, Ness PM. Indications for and adverse effects of red-cell transfusion. N Engl J Med. 2017;377:1261-72. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28953438",
"target":"_blank"
},
"children":[
"PMID: 28953438"
]
},
" doi:10.1056/NEJMra1612789"
]
},
{
"type":"reference",
"children":[
"Goel R, Tobian AAR, Shaz BH. Noninfectious transfusion-associated adverse events and their mitigation strategies. Blood. 2019;133:1831-39. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30808635",
"target":"_blank"
},
"children":[
"PMID: 30808635"
]
},
" doi:10.1182/blood-2018-10-833988"
]
},
{
"type":"reference",
"children":[
"Murphy EL. Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): Implications for blood transfusion safety. Transfus Clin Biol. 2016;23:13-9. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26778839",
"target":"_blank"
},
"children":[
"PMID: 26778839"
]
},
" doi:10.1016/j.tracli.2015.12.001"
]
},
{
"type":"reference",
"children":[
"Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34:171-354. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31180581",
"target":"_blank"
},
"children":[
"PMID: 31180581"
]
},
" doi:10.1002/jca.21705"
]
},
{
"type":"reference",
"children":[
"Panch SR, Montemayor-Garcia C, Klein HG. Hemolytic transfusion reactions. N Engl J Med. 2019;381:150-62. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31291517",
"target":"_blank"
},
"children":[
"PMID: 31291517"
]
},
" doi:10.1056/NEJMra1802338"
]
},
{
"type":"reference",
"children":[
"Semple JW, Rebetz J, Kapur R. Transfusion-associated circulatory overload and transfusion-related acute lung injury. Blood. 2019;133:1840-53. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30808638",
"target":"_blank"
},
"children":[
"PMID: 30808638"
]
},
" doi:10.1182/blood-2018-10-860809"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_hm_t25":{
"id":"mk19_b_hm_t25",
"number":25,
"bookId":"hm",
"title":{
"__html":"Cellular Transfusion Product Modifications"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"7d8815",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 25. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t25"
}
]
},
"Cellular Transfusion Product Modifications"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8af1f1",
"class":"col hd l",
"children":[
"Modification"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4c6f8",
"class":"col hd l",
"children":[
"Notes"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"49ae69",
"class":"cell txt l",
"children":[
"Leukoreduction",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
": decreases number of leukocytes present in transfused erythrocytes or platelets"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0fbb16",
"class":"cell txt l",
"children":[
"Reduces class I HLA alloantibody production and subsequent platelet transfusion refractoriness."
]
},
" ",
{
"type":"p",
"hlId":"9aac09",
"class":"cell txt l",
"children":[
"Decreases febrile nonhemolytic transfusion reactions."
]
},
" ",
{
"type":"p",
"hlId":"062dee",
"class":"cell txt l",
"children":[
"Decreases transmission of CMV."
]
},
" ",
{
"type":"p",
"hlId":"af5e88",
"class":"cell txt l",
"children":[
"Leukoreduction cannot be relied on to prevent transfusion-associated GVHD."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0fc283",
"class":"cell txt l",
"children":[
"Irradiation: prevents replication of lymphocytes and circulating stem cells present in erythrocyte or platelet products"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"20734a",
"class":"cell txt l",
"children":[
"Prevents transfusion-associated GVHD, which is mediated by donor lymphocytes."
]
},
" ",
{
"type":"p",
"hlId":"317391",
"class":"cell txt l",
"children":[
"Indicated in patients with severe immunodeficiency, whether inherited or acquired or following chemotherapy."
]
},
" ",
{
"type":"p",
"hlId":"c121a8",
"class":"cell txt l",
"children":[
"Indicated in immunocompetent patients receiving HLA-matched platelets or transfusions from relatives."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"458caf",
"class":"cell txt l",
"children":[
"Washing: removes proteins remaining in the plasma of erythrocyte and platelet products"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"383837",
"class":"cell txt l",
"children":[
"Used in patients with a history of severe/recurrent allergic reactions, IgA deficiency (when IgA-deficient donors are unavailable)."
]
},
" ",
{
"type":"p",
"hlId":"cd60fe",
"class":"cell txt l",
"children":[
"Reduces the amount of potassium transfused for patients who are at high risk for hyperkalemia."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CMV = cytomegalovirus; GVHD = graft-versus-host disease."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"More than 80% of blood banks in the United States adhere to universal leukoreduction. For those that do not, leukoreduction should be performed for patients who undergo chronic transfusion, those with a history of a febrile hemolytic transfusion reaction, patients who are potential candidates for or recipients of a solid-organ or hematopoietic stem cell transplant, and immunocompromised recipients who are CMV seronegative."
]
]
},
"mk19_b_hm_t26":{
"id":"mk19_b_hm_t26",
"number":26,
"bookId":"hm",
"title":{
"__html":"Plasma-Derived Therapeutic Products"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"7297eb",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 26. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t26"
}
]
},
"Plasma-Derived Therapeutic Products"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"deb105",
"class":"col hd l",
"children":[
"Product"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"29a0e1",
"class":"col hd l",
"children":[
"Indication(s) for Use"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"401df8",
"class":"cell txt l",
"children":[
"Fresh frozen plasma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9296fb",
"class":"cell txt l",
"children":[
"Replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura"
]
},
" ",
{
"type":"p",
"hlId":"bf6a49",
"class":"cell txt l",
"children":[
"Prevention and treatment of coagulopathy from massive transfusion"
]
},
" ",
{
"type":"p",
"hlId":"50efad",
"class":"cell txt l",
"children":[
"Treatment of bleeding associated with multiple acquired clotting factor deficiencies (liver disease, disseminated intravascular coagulation, nonemergent warfarin toxicity)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e262a3",
"class":"cell txt l",
"children":[
"Cryoprecipitate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f63fa",
"class":"cell txt l",
"children":[
"Congenital or acquired fibrinogen deficiency"
]
},
" ",
{
"type":"p",
"hlId":"f6e687",
"class":"cell txt l",
"children":[
"Dysfibrinogenemia"
]
},
" ",
{
"type":"p",
"hlId":"562979",
"class":"cell txt l",
"children":[
"Factor XIII deficiency"
]
},
" ",
{
"type":"p",
"hlId":"2bae2a",
"class":"cell txt l",
"children":[
"Treatment of hemophilia A and von Willebrand disease when a specific factor concentrate is not available"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"feceff",
"class":"cell txt l",
"children":[
"Intravenous immune globulin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"116b11",
"class":"cell txt l",
"children":[
"Acquired or congenital hypogammaglobulinemia"
]
},
" ",
{
"type":"p",
"hlId":"37c530",
"class":"cell txt l",
"children":[
"Autoimmune disorders"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ebe5ae",
"class":"cell txt l",
"children":[
"Albumin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a0bcc",
"class":"cell txt l",
"children":[
"Replacement fluid for plasma exchange"
]
},
" ",
{
"type":"p",
"hlId":"dd5387",
"class":"cell txt l",
"children":[
"Large-volume paracentesis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e821c7",
"class":"cell txt l",
"children":[
"Prothrombin complex concentrates",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d60ecb",
"class":"cell txt l",
"children":[
"Major warfarin-associated hemorrhage"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f580d",
"class":"cell txt l",
"children":[
"Activated factor VII"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"99bd2a",
"class":"cell txt l",
"children":[
"Hemophilia with high-titer inhibitors; acquired hemophilia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3245b6",
"class":"cell txt l",
"children":[
"Factor VIII",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ec1020",
"class":"cell txt l",
"children":[
"Hemophilia A, treatment and prevention of bleeding"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a39344",
"class":"cell txt l",
"children":[
"von Willebrand protein–rich factor VIII",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b,c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64b254",
"class":"cell txt l",
"children":[
"von Willebrand disease, treatment and prevention of bleeding"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e789fb",
"class":"cell txt l",
"children":[
"Factor IX",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"04dfd4",
"class":"cell txt l",
"children":[
"Hemophilia B, treatment and prevention of bleeding"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e702d1",
"class":"cell txt l",
"children":[
"Fibrinogen concentrate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"96b68f",
"class":"cell txt l",
"children":[
"Congenital fibrinogen deficiency, treatment of bleeding"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8ac44",
"class":"cell txt l",
"children":[
"Thrombin",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"165876",
"class":"cell txt l",
"children":[
"Topical application for small vessel bleeding despite standard surgical techniques or when surgical intervention is not feasible"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-12 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3d47b5",
"class":"cell txt l",
"children":[
"Protein C concentrate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a4b34c",
"class":"cell txt l",
"children":[
"Severe congenital protein C deficiency (prevention and treatment of venous thrombosis and purpura fulminans)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-13 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ebb63b",
"class":"cell txt l",
"children":[
"Antithrombin",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5121e4",
"class":"cell txt l",
"children":[
"Hereditary antithrombin deficiency (perisurgical and obstetric procedure prophylaxis and treatment of established venous thrombosis)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-14 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b3a183",
"class":"cell txt l",
"children":[
"α",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-antitrypsin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a14ca8",
"class":"cell txt l",
"children":[
"Congenital α",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-antitrypsin deficiency (high-risk phenotype, α",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-antitrypsin level <11 μmol/L, ≥18 years of age, and airflow obstruction by spirometry)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-15 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c622a8",
"class":"cell txt l",
"children":[
"C1-esterase inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cea6c5",
"class":"cell txt l",
"children":[
"Hereditary angioedema, acute attacks"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Four-factor prothrombin complex concentrate (containing factors II, VII, IX, and X) is preferred over 3-factor prothrombin complex concentrates in which factor VII is missing."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Recombinant product available and preferred as a way of reducing the risk of transmissible infections."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Select plasma-derived factor VIII products are rich in von Willebrand protein."
]
]
},
"mk19_b_hm_t27":{
"id":"mk19_b_hm_t27",
"number":27,
"bookId":"hm",
"title":{
"__html":"Indications for Therapeutic Apheresis<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"09a0b8",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 27. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t27"
}
]
},
"Indications for Therapeutic Apheresis",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7e4782",
"class":"col hd l",
"children":[
"Plasmapheresis/Plasma Exchange"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f29d27",
"class":"cell txt l",
"children":[
"Thrombotic thrombocytopenic purpura"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c5645e",
"class":"cell txt l",
"children":[
"Hyperviscosity syndrome (Waldenström macroglobulinemia and multiple myeloma)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c8c9fb",
"class":"cell txt l",
"children":[
"Paraproteinemic polyneuropathies"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e53ee",
"class":"cell txt l",
"children":[
"Guillain-Barré syndrome (acute inflammatory demyelinating polyneuropathy)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e2828",
"class":"cell txt l",
"children":[
"Chronic inflammatory demyelinating polyradiculoneuropathy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2942f9",
"class":"cell txt l",
"children":[
"Myasthenia gravis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"927d94",
"class":"cell txt l",
"children":[
"ANCA-associated rapidly progressive glomerulonephritis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"af2431",
"class":"cell txt l",
"children":[
"Anti–glomerular basement membrane disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a57d58",
"class":"cell txt l",
"children":[
"Recurrent focal segmental glomerulosclerosis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a12463",
"class":"cell txt l",
"children":[
"Severe, symptomatic cryoglobulinemia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c7e50c",
"class":"cell txt l",
"children":[
"Antibody-mediated renal allograft rejection"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-12 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a80045",
"class":"cell txt l",
"children":[
"Fulminant Wilson disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"df2974",
"class":"col hd l",
"children":[
"Erythrocyte Exchange"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"20b0df",
"class":"cell txt l",
"children":[
"Severe babesiosis",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a030f9",
"class":"cell txt l",
"children":[
"Sickle cell disease with acute cerebral infarct"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"479ea5",
"class":"cell txt l",
"children":[
"Sickle cell disease with severe acute chest syndrome",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"72e680",
"class":"col hd l",
"children":[
"Leukapheresis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fc1391",
"class":"cell txt l",
"children":[
"Hyperleukocytosis syndrome"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ad0533",
"class":"col hd l",
"children":[
"Plateletpheresis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"87b05d",
"class":"cell txt l",
"children":[
"Symptomatic extreme thrombocytosis",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"315e41",
"class":"col hd l",
"children":[
"Extracorporeal Photopheresis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_5-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4e901b",
"class":"cell txt l",
"children":[
"Cardiac allograft rejection, prophylaxis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_5-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"67bb86",
"class":"cell txt l",
"children":[
"Erythrodermic cutaneous T-cell lymphoma/Sézary syndrome"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"94f5aa",
"class":"col hd l",
"children":[
"Selective Blood Component Removal"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_6-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"566e0a",
"class":"cell txt l",
"children":[
"LDL cholesterol for familial hypercholesterolemia"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"This list includes diseases for which apheresis is an accepted part of front-line therapy for a particular indication, either as the sole therapeutic modality or in combination with other therapy. It is not an all-inclusive list."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Erythrocyte exchange for severe malaria is a category II indication (accepted second-line therapy)."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Erythrocyte exchange for acute chest syndrome is a category II indication but recommended by many as first-line therapy for those severely affected."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"The use of plateletpheresis is a category II indication for patients with life-threatening thrombosis or hemorrhage associated with thrombocytosis (e.g., in a patient with essential thrombocytosis)."
],
[
"Data from Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34:171-354. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31180581",
"target":"_blank"
},
"children":[
"PMID: 31180581"
]
},
" doi:10.1002/jca.21705"
]
]
}
}
}